Propranolol 160mg modified-release / Bendroflumethiazide 5mg capsules
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 21 studies.
Reviews & meta-analyses: 1 · Randomised trials: 4 · 2005–2025
Showing all 21 studies, sorted by most relevant.
A. Brunet, D. Saumier, Aihua Liu, et al.
The American journal of psychiatry, 2018
- Memory, Episodic
- Implosive Therapy
- Premedication
J. Hiller, S. Cole, Elizabeth M. Crone, et al.
Clinical Cancer Research, 2019
- Breast Neoplasms
- Propranolol
- Neoplasm Recurrence, Local
B. Dahlöf, Peter S Sever, Neil R. Poulter, et al.
Lancet, 2005
- Adrenergic beta-Antagonists
- Angiotensin-Converting Enzyme Inhibitors
- Antihypertensive Agents
E. Jamileh, Nadeem Gire
P75 Propranolol versus endoscopic variceal ligation for primary prevention of variceal bleeding: a systematic review and meta-analysis, 2025
Yi Ji, Siyuan Chen, Kaiying Yang, et al.
JAMA otolaryngology-- head & neck surgery, 2021
- Adrenergic beta-Antagonists
- Atenolol
- China
V. de Giorgi, M. Grazzini, S. Benemei, et al.
JAMA Oncology, 2017
- Off-Label Use
- Melanoma
- Neoplasm Staging
C. Léauté-Labrèze, E. Dumas de la Roque, T. Hubiche, et al.
The New England journal of medicine, 2008
- Adrenergic beta-Antagonists
- Facial Neoplasms
- Glucocorticoids
Sofia Chatzidou, C. Kontogiannis, D. Tsilimigras, et al.
Journal of the American College of Cardiology, 2018
- Adrenergic beta-Antagonists
- Length of Stay
- Metoprolol
S. Gandhi, M. Pandey, K. Attwood, et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2020
- Adrenergic beta-Antagonists
- Antineoplastic Combined Chemotherapy Protocols
- Melanoma
A. Srinivasan
Annals of Indian Academy of Neurology, 2019
Propranolol is a beta-adrenergic receptor antagonist that was developed by the British scientist Sir James Black primarily for the treatment of angina pectoris, more than 50 years ago. It was not long before several other cardiovascular as well as noncardiovascular therapeutic uses of propranolol were discovered. Propranolol soon became a powerful tool for physicians in the treatment of numerous conditions such as hypertension, cardiac arrhythmias, myocardial infarction, migraine, portal hypertension, anxiety, essential tremors, hyperthyroidism, and pheochromocytoma. Owing to its action at multiple receptor sites, propranolol exerts several central and peripheral effects and is therefore useful in various conditions. Right from reduction in postmyocardial mortality to control of anxiety in performers, propranolol plays an important role in a plethora of medical conditions. Interestingly, even today, newer indications of this age-old drug are being discovered. Moreover, propranolol treatment has been found to be cost-effective when compared to other corresponding treatment options for individual indications. In this article, we attempt to recount the journey of propranolol right from its inception to the present day.
Abstract licence: CC BY-NC-SA
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.